LocKiT Peptide Inhibitor of Nox1 NADPH Oxidase
- Detailed Technology Description
- Technology Description:Researchers have invented a short peptide that interferes with the phosphorylation of Nox1 and prevents its association with other co-factor proteins that are needed for its activation. The net effect is that this peptide “turns off” Nox1, resulting in decreased ROS production and abrogation of ensuing pathogenic phenotypes. Therefore, this peptide has potential to be used as a novel drug to block Nox1 activity in a variety of disease settings.
- *Abstract
-
Patent: pending | US 62/013,916
- Background:
NADPH oxidase is a membrane-bound enzyme complex. It can be found in the plasma membrane as well as in the membranes of neutrophils that degrade infected or abnormal cells. NADPH oxidase is a major cause of atherosclerosis, and its inhibitors may reverse this disease. Atherosclerosis is caused by the accumulation of macrophages containing cholesterol in the artery walls (in the intima). NADPH oxidase produces reactive oxygen species (ROS) which result in the activation of an enzyme that makes the macrophages adhere to the artery wall (by polymerizing actin fibers). This process is counterbalanced by NADPH oxidase inhibitors, and by antioxidants. An imbalance in favor of ROS produces atherosclerosis.
NADPH oxidase plays a vital role in support of our immune system. However, on the surface, it appears to function in a less than desired manner in other locations, resulting in the promotion of deadly disease states. Currently, there is no available method to selectively inhibit activation of Nox1. Available pharmacologic strategies result in the inhibition of other Nox homologs, many of which are necessary for normal physiologic function. Subsequently, such an inhibitor would be of commercial value as a treatment for multiple diseases.
- Technology Description:
Researchers have invented a short peptide that interferes with the phosphorylation of Nox1 and prevents its association with other co-factor proteins that are needed for its activation. The net effect is that this peptide “turns off” Nox1, resulting in decreased ROS production and abrogation of ensuing pathogenic phenotypes. Therefore, this peptide has potential to be used as a novel drug to block Nox1 activity in a variety of disease settings.
- Key Advantages:
- Novel Inhibitory Peptide - Prevents docking of the protein cofactors that are necessary for (Nox1) NADPH oxidase activity.
- Potential applications in the treatment of Hypertension, Atherosclerosis and Cancer.
- *Licensing
- Kenneth Karanja, PhDLicensing AssociateUniversity of Iowa Research Foundation2660 University Capital Center,Iowa City, IA 52242kenneth-karanja@uiowa.edu319-335-4607
- Country/Region
- USA
